• Boehringer partners with Yuhan for liver disease drug pharmaceutical-technology
    July 03, 2019
    Boehringer Ingelheim has partnered with South Korea-based Yuhan for the development of a first-in-class compound to treat nonalcoholic steatohepatitis (NASH) and other related liver disorders.
  • Yuhan licences lung cancer asset to Janssen in $1.25bn deal pharmaceutical-technology
    November 06, 2018
    South Korean pharmaceutical company Yuhan has signed a licensing and cooperation agreement valued at up to $1.25bn with Janssen Biotech to out-license a lung cancer drug candidate called Lazertinib.
PharmaSources Customer Service